Navigation Links
James L. Wittliff, Ph.D., FACB, to Present 'Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System' at the Association for Molecular Pathology Conference, October 30
Date:10/28/2008

w.XceedMolecular.com)

Xceed's vision is to advance molecular diagnostics by successfully translating novel multiplex tests into routine clinical practice and to create robust diagnostic solutions to improve disease outcomes. Our products comprise the award-winning Ziplex System for automated gene-expression analysis (available in the US and Canada for research use only), gene-expression services, and pre-configured arrays - Xpress Chips. Xceed is also developing multiplexed genomic tests for the Ziplex platform, both internally and with strategic partners. Xceed's R&D and manufacturing are headquartered in Toronto, Ontario, with executive offices in Wellesley, Massachusetts.


'/>"/>
SOURCE Xceed Molecular
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
2. Orchid Cellmark Appoints James F. Smith Chief Financial Officer
3. Immunotec Inc. announces appointment of President & CEO James A. Northrop
4. Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence
5. James Webb Space Telescope marks successful completion
6. IRIDEX Announces James Mackaness Will Be Chief Financial Officer
7. Bristol-Myers Squibb Board Elects James M. Cornelius Chairman of the Board
8. PAREXEL International to Present at Raymond James 29th Annual Institutional Investors Conference
9. Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
10. Warner Chilcott Reports the Death of Its Director James Andress
11. James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...A, Neb., Nov. 5 Transgen...ced financial results for the quarter ended Septem...presented in the tables that follow. ,, Third ...s of $366,000 or $0.01 per share for the third qua... or $0.01 per share for the third quarter of 2008....
(Date:11/5/2009)...DIEGO, CA, November 5, 2009 /PRNewswire-FirstCall/...sed on using proprietary taste receptor-based tech...the food, beverage, and ingredient supply industri... financial results for the third quarter ended Sep...he third quarter of 2009, compared to $4.0 million...
(Date:11/5/2009)... Drug safety specialty firm BioSote... and Informatics earned the Certified Professional...ial from the American Society for Training and Dev... Flewell has more than fifteen years of medical co...nd is responsible for the development of the compa...
(Date:11/4/2009)... The Human Anthrax Vaccine Program ...pleted the feature film "A Call to Arms:2009 ...ary "Fatal Immunity: The Human Anthrax Vaccin... and present danger of top secret government scien...ith no accountability to its victims. It is avail...
Breaking Biology Technology:Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 2BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 3BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 4Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 2Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 3Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 4Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 5Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 6Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 7
... and Tragara Pharmaceuticals Inc. today announced ...se to Tragara to develop and commercialize its nov...terms of the agreement S*BIO is eligible to receiv...s an upfront fee, development and sales milestone ...onally, S*BIO will perform certain preclinical act...
... (Nasdaq: NLTX ), today announced that it will f...ic peptide franchise, including CD-NP which is in ...CU-NP which is a pre-clinical compound. Nile will ...urn license rights for the compound to Dr. Cesare ... unable to continue to pursue the development of 2...
...ex: DDD ) today announced that the U. S. Food an...Response letter for its Abbreviated New Drug Appli...n, filed by SCOLR on August 5, 2008, seeks approva...t based on its patented Controlled Delivery Techno...e letter requests additional information, all of w...
Other Biology Technology:S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317 2S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317 3Nile Therapeutics Announces Focus on CD-NP for Acute Heart Failure and Termination of 2NTX-99 Program 2Nile Therapeutics Announces Focus on CD-NP for Acute Heart Failure and Termination of 2NTX-99 Program 3Nile Therapeutics Announces Focus on CD-NP for Acute Heart Failure and Termination of 2NTX-99 Program 4FDA Issues Complete Response Letter to SCOLR Pharma's Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine 2FDA Issues Complete Response Letter to SCOLR Pharma's Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine 3
(Date:11/6/2009)...h anniversary this month of the publication of On ...iological Sciences (AIBS) is publishing open acces...and his historic insights into evolution. , The t...of California, Berkeley, and James T. Costa of Wes...yths About Charles Darwin," appeared in the Octobe...
(Date:11/5/2009)...ion of Biology Teachers (NABT) will recognize Leon... at Naugatuck Valley Community College (NVCC) in W...cation Award during the NABT annual professional d...09 in Denver, Colorado. , The Evolution Educatio...f Biological Sciences,(AIBS) and Biological Scien...
(Date:11/4/2009)...n natural science) , United States Using Less ... today than it did 35 years ago, despite a 30 perc... partly attributable to alternative cooling method...stems. According to the latest USGS water use repo...ates goes to cooling thermoelectric power plants. ...
Breaking Biology News(10 mins):Biologists, educators recognize excellence in evolution education 2USGS science picks 2USGS science picks 3USGS science picks 4USGS science picks 5USGS science picks 6USGS science picks 7Cardiac stem cell trial seeks to treat some heart attack patients 58592 1Cardiac stem cell trial seeks to treat some heart attack patients 58592 2Cardiac stem cell trial seeks to treat some heart attack patients 58592 3Study explores how life experiences contribute to the biological changes of Alzheimers 10197 1Study explores how life experiences contribute to the biological changes of Alzheimers 10197 2Study explores how life experiences contribute to the biological changes of Alzheimers 10197 3FDA Approves PRE PEN Penicillin Allergy Test 58590 1FDA Approves PRE PEN Penicillin Allergy Test 58590 2
...ctedly from the ocean to rescue a dying coral reef...dramatic flair of comic-book superhero Batman, a b...d to death by seaweed ?although the fish was never...s at the ARC Centre of Excellence for Coral Reef S...are lost to weed were astonished when, after remov...
...tic increase in testicular cancer, now the most co...asian men, is the focus of a five-year, $5.5 milli...ublic Health researcher Tongzhang Zheng. , Testicu...his study will provide important information on po...rs,?said Zheng, professor and head of the Division...
...any of them had narrow, pointed teeth, which were ...ing them. But how did they then grind their food? ...they were helped by stones which they swallowed. I...d of ,gastric mill,. But this assumption does not ...ies of Bonn and Tübingen have now proved. Their re...
Other Biology News:Batfish to the rescue! 2Dinosaurs -- stones did not help with digestion 2Dinosaurs -- stones did not help with digestion 3
Custom siRNA, HPLC purified, annealed from Ambion
Silencer Pre-designed siRNA, standard purity from Ambion
Silencer Pre-designed siRNA, standard purity, annealed from Ambion
Silencer Pre-designed siRNA, HPLC purified, annealed from Ambion
Biology Products: